# Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older

> **NCT06460506** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 50 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** ELX/TEZ/IVA
- **DRUG:** IVA

## Key facts

- **NCT ID:** NCT06460506
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-21
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06460506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06460506, "Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06460506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*